Vanda Pharmaceuticals Inc. (VNDA) is on the cusp of key regulatory milestones that have the potential to drive significant growth and expand its therapeutic footprint in 2026 and beyond.
This global biopharmaceutical company currently markets three approved therapies - Fanapt, Hetlioz, and Ponvory - and has two drug candidates awaiting FDA approval for their first indications.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com